{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:12:19Z","timestamp":1789420339971,"version":"build-2803163510"},"publisher-location":"New York, NY","reference-count":21,"publisher":"Springer US","isbn-type":[{"value":"9781071618912","type":"print"},{"value":"9781071618929","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1892-9_5","type":"book-chapter","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T17:06:35Z","timestamp":1639674395000},"page":"75-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phage T7 as a Potential Platform for Vaccine Development"],"prefix":"10.1007","author":[{"given":"Chuan Loo","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chean Yeah","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Wooi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"5_CR1","unstructured":"WHO (2020) Archived: WHO Timeline\u2014COVID-19. https:\/\/www.who.int\/news-room\/detail\/27-04-2020-who-timeline%2D%2D-covid-19. Accessed Aug 2020"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.virol.2019.03.006","volume":"531","author":"F Maurier","year":"2019","unstructured":"Maurier F, Beury D, Fl\u00e9chon L, Varr\u00e9 J-S, Touzet H, Goffard A, Hot D, Caboche S (2019) A complete protocol for whole-genome sequencing of virus from clinical samples: application to coronavirus OC43. Virology 531:141\u2013148. https:\/\/doi.org\/10.1016\/j.virol.2019.03.006","journal-title":"Virology"},{"issue":"12","key":"5_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrmicro3564","volume":"13","author":"GPC Salmond","year":"2015","unstructured":"Salmond GPC, Fineran PC (2015) A century of the phage: past, present and future. Nat Rev Microbiol 13(12):777\u2013786. https:\/\/doi.org\/10.1038\/nrmicro3564","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"5_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","volume":"1","author":"C Loc-Carrillo","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1(2):111\u2013114. https:\/\/doi.org\/10.4161\/bact.1.2.14590","journal-title":"Bacteriophage"},{"issue":"7","key":"5_CR5","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","volume":"49","author":"A Bruttin","year":"2005","unstructured":"Bruttin A, Br\u00fcssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49(7):2874\u20132878. https:\/\/doi.org\/10.1128\/AAC.49.7.2874-2878.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00262-013-1443-5","volume":"62","author":"GS Shukla","year":"2013","unstructured":"Shukla GS, Krag DN, Peletskaya EN, Pero SC, Sun Y-J, Carman CL, McCahill LE, Roland TA (2013) Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies. Cancer Immunol Immunother 62(8):1397\u20131410. https:\/\/doi.org\/10.1007\/s00262-013-1443-5","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"5_CR7","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1158\/0008-5472.can-05-4441","volume":"66","author":"DN Krag","year":"2006","unstructured":"Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C (2006) Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 66(15):7724\u20137733. https:\/\/doi.org\/10.1158\/0008-5472.can-05-4441","journal-title":"Cancer Res"},{"issue":"4","key":"5_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jmv.20479","volume":"77","author":"GH Tan","year":"2005","unstructured":"Tan GH, Yusoff K, Seow HF, Tan WS (2005) Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7. J Med Virol 77(4):475\u2013480. https:\/\/doi.org\/10.1002\/jmv.20479","journal-title":"J Med Virol"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vetmic.2017.04.023","volume":"205","author":"H Xu","year":"2017","unstructured":"Xu H, Bao X, Lu Y, Liu Y, Deng B, Wang Y, Xu Y, Hou J (2017) Immunogenicity of T7 bacteriophage nanoparticles displaying G-H loop of foot-and-mouth disease virus (FMDV). Vet Microbiol 205:46\u201352. https:\/\/doi.org\/10.1016\/j.vetmic.2017.04.023","journal-title":"Vet Microbiol"},{"issue":"13","key":"5_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.vaccine.2003.10.047","volume":"22","author":"JB March","year":"2004","unstructured":"March JB, Clark JR, Jepson CD (2004) Genetic immunisation against hepatitis B using whole bacteriophage \u03bb particles. Vaccine 22(13):1666\u20131671. https:\/\/doi.org\/10.1016\/j.vaccine.2003.10.047","journal-title":"Vaccine"},{"issue":"12","key":"5_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/2326-6066.CIR-18-0179","volume":"6","author":"C Bartolacci","year":"2018","unstructured":"Bartolacci C, Andreani C, Curcio C, Occhipinti S, Massaccesi L, Giovarelli M, Galeazzi R, Iezzi M, Tilio M, Gambini V, Wang J, Marchini C, Amici A (2018) Phage-based anti-HER2 vaccination can circumvent immune tolerance against breast cancer. Cancer Immunol Res 6(12):1486. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0179","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"5_CR12","doi-asserted-by":"publisher","first-page":"e01926","DOI":"10.1128\/mBio.01926-18","volume":"9","author":"P Tao","year":"2018","unstructured":"Tao P, Mahalingam M, Zhu J, Moayeri M, Sha J, Lawrence WS, Leppla SH, Chopra AK, Rao VB (2018) A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague. mBio 9(5):e01926\u2013e01918. https:\/\/doi.org\/10.1128\/mBio.01926-18","journal-title":"mBio"},{"issue":"43","key":"5_CR13","doi-asserted-by":"publisher","first-page":"26819","DOI":"10.1074\/jbc.271.43.26819","volume":"271","author":"AH Rosenberg","year":"1996","unstructured":"Rosenberg AH, Griffin K, Washington MT, Patel SS, Studier FW (1996) Selection, identification, and genetic analysis of random mutants in the cloned primase\/helicase gene of bacteriophage T7. J Biol Chem 271(43):26819\u201326824","journal-title":"J Biol Chem"},{"issue":"9","key":"5_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045765","volume":"7","author":"H Hashemi","year":"2012","unstructured":"Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T (2012) Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza a virus challenge. PLoS One 7(9):e45765. https:\/\/doi.org\/10.1371\/journal.pone.0045765","journal-title":"PLoS One"},{"issue":"11","key":"5_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049539","volume":"7","author":"S Pouyanfard","year":"2012","unstructured":"Pouyanfard S, Bamdad T, Hashemi H, Bandehpour M, Kazemi B (2012) Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles. PLoS One 7(11):e49539. https:\/\/doi.org\/10.1371\/journal.pone.0049539","journal-title":"PLoS One"},{"issue":"1","key":"5_CR16","first-page":"241","volume":"32","author":"M Shadidi","year":"2008","unstructured":"Shadidi M, S\u00f8rensen D, Dybwad A, Furset G, Sioud M (2008) Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma. Int J Oncol 32(1):241\u2013247","journal-title":"Int J Oncol"},{"issue":"3","key":"5_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10330-006-0474-1","volume":"5","author":"D Liu","year":"2006","unstructured":"Liu D, Tang L, Zhou C, Tan L (2006) Immunotherapy of EGFR-positive tumor based on recombinant EGFR phage vaccine. Chin-Ger J Clin Oncol 5(3):189\u2013193. https:\/\/doi.org\/10.1007\/s10330-006-0474-1","journal-title":"Chin-Ger J Clin Oncol"},{"issue":"10","key":"5_CR18","first-page":"1221","volume":"25","author":"X-H Li","year":"2006","unstructured":"Li X-H, Tang L, Liu D, Sun H-M, Zhou C-C, Tan L-S, Wang L-P, Zhang P-D, Zhang S-Q (2006) Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 25(10):1221\u20131226","journal-title":"Ai Zheng"},{"issue":"9","key":"5_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/laban1005-39","volume":"34","author":"WT Golde","year":"2005","unstructured":"Golde WT, Gollobin P, Rodriguez LL (2005) A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim 34(9):39\u201343. https:\/\/doi.org\/10.1038\/laban1005-39","journal-title":"Lab Anim"},{"issue":"2","key":"5_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.virol.2012.09.018","volume":"434","author":"EM Adriaenssens","year":"2012","unstructured":"Adriaenssens EM, Lehman SM, Vandersteegen K, Vandenheuvel D, Philippe DL, Cornelissen A, Clokie MRJ, Garc\u00eda AJ, De Proft M, Maes M, Lavigne R (2012) CIM\u00ae monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles. Virology 434(2):265\u2013270. https:\/\/doi.org\/10.1016\/j.virol.2012.09.018","journal-title":"Virology"},{"issue":"21","key":"5_CR21","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jchromb.2010.05.028","volume":"878","author":"R Monjezi","year":"2010","unstructured":"Monjezi R, Tey BT, Sieo CC, Tan WS (2010) Purification of bacteriophage M13 by anion exchange chromatography. J Chromatogr B 878(21):1855\u20131859. https:\/\/doi.org\/10.1016\/j.jchromb.2010.05.028","journal-title":"J Chromatogr B"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1892-9_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T05:19:39Z","timestamp":1641014379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1892-9_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"ISBN":["9781071618912","9781071618929"],"references-count":21,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1892-9_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"17 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}